Request Samples
Request Samples
Sample Closet

 

Request samples for your practice

BRILINTA® (ticagrelor) Dosing Card
BRILINTA® (ticagrelor) Dosing Card
BRILINTA Dosing Card for patients with Acute Ischemic Stroke (NIHSS ≤5) or High-Risk TIA

 

Download a Dosing Card for BRILINTA in Acute Ischemic Stroke (NIHSS ≤5) or High-Risk TIA

2021 AHA/ASA Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2021 AHA/ASA Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
 
2021 AHA/ASA Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

 

Download the recommendations for BRILINTA

Clinical trial reprints

The following links to journals are provided as an educational service by AstraZeneca Pharmaceuticals LP. The articles linked herein may include some information for AstraZeneca products that is not contained in or is inconsistent with the FDA-approved Prescribing Information. Some authors may have a financial interest in AstraZeneca and/or may have received compensation from AstraZeneca. AstraZeneca recommends use of its products only in accordance with the approved Prescribing Information. Prescription drugs used outside of an approved indication may not be eligible for reimbursement by third-party payors, including Medicare or Medicaid.

BRILINTA in acute coronary syndrome

PLATO

Wallentin L et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes

NSTE-ACS in PLATO
NSTE-ACS IN PLATO

Lindholm D et al. Ticagrelor vs clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial

PLATO Safety
PLATO safety

Becker RC et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial

Post Hoc Analysis in CKD PLATO
Post hoc analysis CKD in PLATO

James S et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial

SWEDEHEART Real-World Evidence
SWEDEHEART Real-world evidence

Sahlén A et al. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry

BRILINTA in prior MI

PEGASUS
PEGASUS

Bonaca MP et al. Long-term use of ticagrelor in patients with prior myocardial infarction

BRILINTA in high-risk CAD without history of MI or stroke

THEMIS
THEMIS

Steg PG et al. Ticagrelor in patients with stable coronary disease and diabetes

THEMIS-PCI
THEMIS-PCI

Bhatt DL et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomized trial

BRILINTA in acute ischemic stroke or high-risk TIA

THALES
THALES

Johnston SC et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA

THALES IPSILATERAL ATHEROSCLEROTIC STENOSIS SUBGROUP
THALES IPSILATERAL ATHEROSCLEROTIC STENOSIS SUBGROUP

Amarenco P et al. Ticagrelor added to aspirin in acute nonsevere ischemic stroke or transient ischemic attack of atherosclerotic origin

THALES subsequent disabling stroke prespecified analysis
THALES subsequent disabling stroke prespecified analysis

Amarenco P et al. Ticagrelor added to aspirin in acute ischemic stroke or transient ischemic attack in prevention of disabling stroke

Pharmacokinetics/Pharmacodynamics of BRILINTA

It is not known how pharmacology or chemical class correlates to clinical efficacy or safety results.

PLATO Genetic Sub Study
PLATO genetic substudy

Wallentin L et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

Onset and Offset of BRILINTA
Onset and offset of BRILINTA

Gurbel PA et al. Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor in Patients With Stable Coronary Artery Disease

ACS=acute coronary syndrome; CAD=coronary artery disease; MI=myocardial infarction; NSTE-ACS=non–ST-elevation acute coronary syndrome; PEGASUS=Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin; PLATO=PLATelet inhibition and patient Outcomes; RRR=relative risk reduction; STEMI=ST-elevation MI; THALES=Acute STroke or Transient IscHemic Attack Treated with TicAgreLor and Aspirin for PrEvention of Stroke and Death; THEMIS=Effect of Ticagrelor on Health Outcomes in DiabEtes Mellitus Patients Intervention Study; TIA=transient ischemic attack; T2D=type 2 diabetes.